Drug intelligence / Profile preview

Probiotic A

Development stage: Preclinical
Lead developer: Archer Daniels Midland
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Probiotic A is a specific probiotic strain developed by The Archer-Daniels-Midland Company. It is being investigated as a dietary supplement for adults experiencing mild to moderate gastrointestinal discomfort. The intervention involves a 6-week administration period, aiming to assess its safety and efficacy in improving gut health, as measured by participant questionnaires and analysis of blood and stool samples.

Targets

PRR (Pattern recognition receptors)

Beyond the preview

Go deeper on Probiotic A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Probiotic A.

Explore the full profile